USPTO 2015–2025 USPTO PatentsView US Corporation

Novozymes, Inc.

USPTO PatentsView assignee record - 208 granted patents across 24 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

RSS updates for this company

The verdict

According to USPTO PatentsView, Novozymes ranks #1,932 of 49,997 tracked US assignees by granted-patent volume, with 208 patents across 24 technology areas.

#1,932
of 49,997 US assignees by volume
Top 11%
by Innovation Score (51.5/100)
26.0
avg claims per patent
-84%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1932 · US Corporation #1,932 · 208 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MID 208 grants
  • TOP-DECILE #1,932/49,997
  • PHOTO-FINISH Becton Dickinson…
  • CPC-FOCUS C12N · 24 areas
  • INNOV-PAR 51.5/100
  • CLAIMS-DENSE 26.0 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -84% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Becton Dickinson France (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Novozymes

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Novozymes's Innovation Score is 51.5/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Novozymes's grants concentrate

Novozymes, Inc. is a focused PatentsView assignee: 24 CPC subclasses with 95.7% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2017 (41 grants) versus a trough of 1 in 2023. By volume, Novozymes sits between Becton Dickinson France and Fujitsu General Limited.

Novozymes's three-year grant acceleration

From 2019–2021 to 2022–2024, Novozymes, Inc. moved from 49 to 5 grants (0.10x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #3,173. See the growth leaderboard.

Who files at Novozymes's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Novozymes holds 208 patents at rank #1,932, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Novozymes

By rank, the assignees closest to #1,932 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Novozymes's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novozymes, neither rank-band nor same-CPC leaders (those blocks stay above).

Novozymes's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 11% higher than 89% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

01020304050 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Novozymes, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 36 17.3%
2016 38 18.3%
2017 41 19.7%
2018 36 17.3%
2019 25 12.0%
2020 13 6.3%
2021 11 5.3%
2022 3 1.4%
2023 1 0.5%
2024 1 0.5%
2025partial year 3 1.4%

Which technologies does Novozymes, Inc. patent most?

Top 15 of 24 technology areas

Where it ranks

Overall rank by patents

#1,932

of 49,997 tracked assignees

Innovation Score

51.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Novozymes, Inc.'s patent record in context - here's where to go next.

  • Novozymes, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 95.7% of its portfolio - see every assignee active in that class. Explore C12N
  • Ranked #1,932 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Novozymes, Inc. against Becton Dickinson France, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 51.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.